Association between longitudinal changes in striatal dopamine transporter uptake and clinical features of dementia with Lewy bodies

Abstract

BackgroundIt is widely known that there is low striatal 123I‐2β‐Carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐ fluoropropyl) nortropane (123I‐FP‐CIT) dopamine transporter single photon emission tomography (DaT‐SPECT) uptake in patients with dementia with Lewy bodies (DLB). No studies to date have analyzed the association between longitudinal changes of clinical features and DaT uptake in patients with Parkinson syndrome, particularly those with DLB. The aim of this study was to investigate the association between the longitudinal changes in DaT uptake and the severity of parkinsonism and cognitive function in DLB patients.MethodsA total of 35 outpatients with probable DLB who underwent DaT‐SPECT twice (at the initial examination and the follow‐up period) in the Memory Disorder Clinic at the Department of Geriatric Medicine, Tokyo Medical University, were enrolled in this study between April 2014 and September 2020. The correlation between annual changes in DaT uptake and clinical features (cognitive function decline and parkinsonism) of the patients was analyzed.ResultsA significant correlation was detected between annual changes in parkinsonism symptom severity and DaT uptake in the left posterior putamen (r = −0.39, P = 0.03), and between Mini‐Mental State Examination scores and DaT uptake in all regions except the right posterior putamen (P < 0.05) in patients with DLB.ConclusionsOur results suggested that the pathway from the ventrolateral tier of the substantia nigra to the putamen might be more crucial for motor function than other pathways, not only in Parkinson's disease but also in DLB.